{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","lowerLimit":"0.1690","upperLimit":"0.5623","value":"0.3636"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"* Acute GVHD rate and worst severity is noted\n* 4 organ categories (skin, liver, lower GI, and upper GI)\n* Skin: Grade I: 1-2 , Grade II: 3, Grade III: N/A, Grade IV: 4\n* Liver: Grade I: 0, Grade II: 1, Grade III: 2-4, Grade IV: N/A\n* Lower GI: Grade I: 0, Grade II: 1: Grade II: 2-3: Grade IV: 4\n* Upper GI: Grade I: 0, Grade II: 1, Grade III: N/A, Grade IV: N/A\n* The cumulative incidence of grade 2-4 acute GVHD was determined using competing risk analysis. Competing risks for acute GVHD were death, relapse, and graft failure.","dispersionType":"95% Confidence Interval","groups":[{"description":"-Donors will receive subcutaneous (SC) BL-8040 in the morning (Day 1) followed by leukapheresis approximately 180 minutes (up to 270 minutes) after the injection per institutional protocol. If the donor does not reach the collection goal for mobilization (≥ 5.0 x 10\\^6 CD34+ cells/kg), a second leukapheresis will be performed on Day 2 (24 hours ± 2 hours from the BL-8040 injection) in an effort to reach a total of ≥ 5 x 10\\^6 CD34+ cells/kg and at least ≥ 2 x 10\\^6 CD34+ cells/kg from the combined collections.","id":"OG000","title":"Arm 1: Donors"},{"description":"-All or part of the leukapheresis product will be infused into the recipient per institutional guidelines. The day of the infusion will be considered Day 0; if the infusion occurs over multiple days, the final day of infusion will be considered Day 0","id":"OG001","title":"Arm 2: Recipients"}],"paramType":"NUMBER","populationDescription":"-Donors are not evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Day 100","title":"Cumulative Incidence of Grade 2-4 Acute Graft Versus Host Disease (GvHD) as Measured by Minnesota Acute GVHD Criteria (Arm 2 Recipients Only)","type":"SECONDARY","unitOfMeasure":"proportion of participants"}